MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

Data from the phase 3 MARIPOSA-2 study support the supplemental biologics license application for amivantamab plus chemotherapy in EGFR-mutated advanced or metastatic non–small cell lung cancer.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Adagrasib, which now has a positive CHMP opinion, was previously examined as part of the phase 1/2 KRYSTAL-1 study.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.